Urokinase-Derived Peptide A6
DRACPC ID DRACPC0101
Active Ingredients Urokinase-Derived Peptide A6
Description An octapeptide (amino acids 136-143) derived from the proteolytic enzyme urokinase plasminogen activator (uPA), with potential antineoplastic activity. A6 is derived from the nonreceptor-binding domain and connecting region of urokinase. Administration of A6 inhibits the interaction of uPA with its receptor uPAR, and may inhibit endothelial cell motility and tumor cell invasion. uPA and uPAR promote extracellular matrix degradation and growth factor activation and correlate positively with angiogenesis, cancer cell invasion and metastasis.
Synonyms A6; ACETYL-LYS-PRO-SER-SER-PRO-PRO-GLU-GLU-NH2; uPA-derived Peptide A6; urokinase plasminogen activator (uPA)-derived peptide A6; Urokinase-Derived Peptide A6
Type Biotech
Disease Ovarian epithelial cancer, Fallopian tube cancer, Primary peritoneal cancer.
Classification
Peptide and derivative Antiangiogenesis agent
Structure Information
Molecular Formula Not available
Molecular Weight Not available
Active Sequence KPSSPPEE
Sequence Length 8
Modification C-terminal Ac, N-terminal NH2
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID Not available
DrugBank Accession Number Not available
NCI Thesaurus Code C91709
UNII KM64V5W7RA GSRS
CAS 220334-14-5
Drug approval
Drug indication
Investigated for use/treatment in persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00939809 | A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | Fallopian Tube Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Primary Peritoneal Carcinoma; Recurrent Ovarian Carcinoma; Undifferentiated Ovarian Carcinoma | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
